Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus B
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Administration
- Intranasal
01
Overview
Respiratory Syncytial Virus B (RSV-B) is a live viral challenge agent (inoculum) used in controlled human infection challenge (CHIC) studies. Specifically, the RSV B-I54 strain is utilized by Imperial College London in the CHIRP02 study to evaluate immune responses in healthy older adults (aged 65–75 years). Unlike a therapeutic drug or vaccine, this agent is intranasally administered to deliberately induce a mild-to-moderate RSV infection, allowing researchers to monitor viral shedding, symptomatology, and age-related immune dynamics in a controlled environment. The program is led by Professor Christopher Chiu and supported by the Medical Research Council (MRC) and GSK.
- Other names
- RSV-BRespiratory Syncytial Virus Subtype BRSV B challenge agent
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))TLR4 (Toll-like receptor 4)CX3CR1 (C-X3-C motif chemokine receptor 1)Host cell plasma membrane lipidsPolyreactive immunoglobulin M B-cell receptor
Beyond the preview
Go deeper on respiratory syncytial virus B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus B.